Behcet Syndrome Clinical Trial
Official title:
Phase II Study, Evaluation of Low Dose Natural Human Interferon Alpha Administered by the Oral Mucosal Route in the Treatment of Behçet's Disease
The purpose of this study is to determine the safety and efficacy of natural human interferon alpha (IFN alpha) on size, number, incidence and pain of oral ulcers associated with Behçet's Disease (BD).
Behçet's disease is a severe chronic relapsing inflammatory disorder marked by oral and
genital ulcers, uveitis and skin lesions, as well as varying multisystem involvement
including the joints, blood vessels, central nervous system, and gastrointestinal tract.
Oral ulcers are the initial symptom for most of Behçet's cases and are the single
manifestation of the disease required for an official diagnosis, along with two other
hallmark symptoms.
Ninety (90) patients will be enrolled in a randomized, parallel, double-blind,
placebo-controlled study to evaluate the effectiveness of low dose natural human IFN α
administered by the oral mucosal route in reducing the number, size, incidence and pain of
oral ulcers in patients with Behçet's disease.
The clinical trial will consist of 3 groups of patients randomized in a 1:1:1 ratio to twice
daily receive 2 lozenges containing 500 IU IFN α(2,000 IU daily, n=30), one active (500 IU)
and one placebo lozenge (1,000 IU daily, n=30) or 2 placebo lozenges (n=30). Subjects will
be monitored weekly over an initial 4 weeks of treatment and then bi-weekly over an
additional 8 weeks of treatment. Medication will be self-administered as 2 lozenges taken
twice daily (morning and evening). Oral lesions will be counted and measured at each study
visit, and patients will answer a series of questionnaires. Results will be subjected to
statistical analysis at the completion of the study, with change in total ulcer burden of a
patient, a measurement of the total oral mucosal surface area involved with ulcerous lesions
at each visit, serving as the primary endpoint. The total ulcer burden from each treated
visit will be compared to the baseline total ulcer burden and the amount of change
determined. Patients with a 75% decrease in total ulcer burden will be considered
responders.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03274648 -
Dietary Interventions and Butyrate Production in Behçet's Patients
|
N/A | |
Terminated |
NCT01693653 -
Tocilizumab for the Treatment of Behcet's Syndrome
|
Phase 2 | |
Completed |
NCT04961463 -
Evaluation of the Psychoeducation Program Given to Behcet's Patients in the Context of the Roy Adaptation Model
|
N/A | |
Completed |
NCT05142995 -
Sleep Related Breathing Disorders, Anxiety, Depression and Quality of Life Assessment in Behcet's Disease
|
||
Recruiting |
NCT00931957 -
Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease
|
N/A | |
Completed |
NCT03514056 -
Frequency of Fibromyalgia in Behcet Disease
|
||
Not yet recruiting |
NCT03771768 -
Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's Disease
|
N/A | |
Terminated |
NCT03554161 -
Tocilizumab for the Treatment of Refractory Behcet's Uveitis
|
Phase 2 | |
Recruiting |
NCT04738864 -
Neuro-ultrasound Assessment in Behcet's Disease
|
N/A | |
Completed |
NCT03264391 -
Evaluation of Macular Vascular Changes in Behcet's Disease Using Optical Coherence Tomography Angiography
|
||
Completed |
NCT04386824 -
Erectile Dysfunction in Patients With Non Ocular Behçet's Disease
|
||
Completed |
NCT03962335 -
Gut Microbiota and Behcet's Syndrome: a Dietary Intervention Trial (MAMBA Study)
|
N/A | |
Completed |
NCT01532570 -
Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
|
Phase 3 | |
Not yet recruiting |
NCT04186559 -
Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers
|
Phase 2 | |
Terminated |
NCT04218565 -
Golimumab for the Treatment of Refractory Behcet's Uveitis
|
Phase 2 | |
Not yet recruiting |
NCT03747354 -
Assessment of Disease Activity in Behcet by Complete Blood Count
|
N/A | |
Recruiting |
NCT05200715 -
AutoInflammatory Disease Alliance Registry (AIDA)
|
||
Completed |
NCT05098678 -
Zinc Supplementation and Behçet's Syndrome
|
N/A | |
Completed |
NCT00866359 -
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease
|
Phase 2 | |
Completed |
NCT05032248 -
Uses of Tacrolimus in Behcet Disease
|
N/A |